Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing hypomethylating agents in myelodysplastic syndromes

14 Jan 2012

Abstract excerpt

PURPOSE OF REVIEW: Hypomethylating agents (HMAs) improve the outcome of higher-risk myelodysplastic syndromes (MDS) and provide multilineage response in lower-risk patients but their results must be optimized, especially as the poor outcome of patients after HMA failure is now established. RECENT FINDINGS: Current efforts include evaluation of novel outpatient administration schedules and routes, improving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Blood disorders and treatments
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22248878
DOI: 10.1097/moh.0b013e32834ff58a

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing hypomethylating agents in myelodysplastic syndromesPMID 22248878Read ↗

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selectionSemantic proximity Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Established and emerging targeted therapies in the myelodysplastic syndromes.Semantic proximity Read ↗

The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.Semantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Semantic proximity Read ↗

Current and emerging strategies for management of myelodysplastic syndromes.Semantic proximity Read ↗

Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agentsSemantic proximity Read ↗

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.